That's the answer. Here it is as a table, before anything else.
| Dose | Earliest week you could reach it* | How it fits the labeled schedule |
|---|---|---|
| 2.5 mg | Week 1 | Starting dose only — not approved as a maintenance dose |
| 5 mg | Week 5 | Maintenance dose for weight reduction |
| 7.5 mg | Week 9 | A step on the way up — not a listed maintenance dose |
| 10 mg | Week 13 | Maintenance dose for weight reduction and sleep apnea |
| 12.5 mg | Week 17 | A step on the way up — not a listed maintenance dose |
| 15 mg | Week 21 | Maintenance dose and the maximum |
* We calculated this column ourselves by stacking the label's minimum four-week gaps end to end. It is the fastest schedule the label allows. It is not a plan. Your prescriber decides whether and when you move up.
Now here's the part a simple Zepbound dose chart leaves out.
The milligrams are the easy part. They come from the same FDA-approved label. What actually trips people up is the container. The current FDA-approved label lists four Zepbound presentations, and the same 10 mg dose is 0.5 mL of liquid in one and 0.6 mL in another. A single-dose device can spend a total of 21 days at room temperature. A multi-dose vial or KwikPen has three separate throw-away limits, and the first-use clock can strand medicine someone already paid for.
We'll get to all of it. Start here.
Best for you if / Not for you if
This page will help you if:
- You've been handed a pen, a vial, or a KwikPen and you're not sure which one you have.
- You want to know where 2.5, 5, 7.5, 10, 12.5, or 15 mg fits in the schedule.
- You saw 0.5 mL on one box and 0.6 mL on another and stopped.
- You missed a shot and need the rule.
- You want to know when to throw a device away.
- You're trying to work out which form your insurance will actually pay for.
This page cannot tell you:
- Whether you should move up a dose this month.
- What dose to restart on after several missed weeks.
- How to get a smaller dose out of a KwikPen.
- How to split a single-dose vial.
The first two are individual prescriber calls. The last two are not approved ways to use the device, and the official instructions tell you not to do them.
The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.
The one thing we can't do for you
Let's get this out of the way early, because it changes how you should read everything below.
This chart cannot tell you whether you personally should move up to the next dose. We can show you the FDA-labeled schedule down to the week. We can show you what's in every device. We can't look at your side effects, your weight trend, your other medications, or your history — and those are what the decision actually turns on.
So we didn't build a page that pretends otherwise. We built the opposite: a page that nails down every single thing that is fixed and knowable, so that when you talk to your prescriber, the only thing left to discuss is the part that genuinely requires their judgment.
Every factual claim below is verifiable. We'll show you where each piece comes from.
Jump to what you need:
The full Zepbound dose chart · Do I have to move up every 4 weeks? · Which doses are maintenance doses? · Pen vs vial vs KwikPen · Why 0.5 mL vs 0.6 mL · Can I count clicks? · Which form fits me? · Identify my device · Storage and throw-away dates · The 30-day KwikPen clock · Unused-dose cost · What each form costs · Supplies · Missed a dose · Before you move up · What we verified · FAQ
What is the Zepbound dose chart?
Zepbound (tirzepatide) is a once-weekly shot that comes in six strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg. The FDA-approved label starts every indication at 2.5 mg once weekly for four weeks, then increases to 5 mg once weekly. After that, the dose may go up in 2.5 mg steps, but only after at least four weeks at the current dose. The maximum is 15 mg once weekly. ([Prescribing Information][1])
Here is the full version, with what each strength is actually for.
| Strength | Earliest week possible* | Role in weight treatment | Role in sleep apnea treatment |
|---|---|---|---|
| 2.5 mg | Week 1 | Starting dose only. It is not approved as a maintenance dose. | Starting dose only |
| 5 mg | Week 5 | Maintenance option | A step up only — not a listed maintenance dose for OSA |
| 7.5 mg | Week 9 | A step up only | A step up only |
| 10 mg | Week 13 | Maintenance option | Maintenance option |
| 12.5 mg | Week 17 | A step up only | A step up only |
| 15 mg | Week 21 | Maintenance option and the maximum | Maintenance option and the maximum |
* Our calculation, not the manufacturer's. It assumes every increase happens at the earliest moment the label allows. Treat it as a floor, not a schedule.
Why we put an "earliest week" column on this chart
The label gives you the ingredients for the calculation — four weeks at 2.5 mg, then 2.5 mg steps no sooner than every four weeks — but it never adds them up. So we did.
Four weeks at each of five steps before you land on 15 mg puts the earliest possible arrival at week 21, or about five months in.
That number is useful in both directions. If someone told you you'd be at 15 mg by month two, that isn't possible under the label. And if you're at week 30 and still on 10 mg, you are not behind — 10 mg is a listed maintenance dose.
What 2.5 mg actually is
It's a starting dose. The label says 2.5 mg is used to begin treatment and is not approved as a maintenance dose. You take it for four weeks, then the label directs an increase to 5 mg. The gradual start is meant to reduce the risk of stomach and other gastrointestinal side effects.
That doesn't mean 2.5 mg does nothing. It means the label doesn't back it as a place to park long-term.
What 7.5 mg and 12.5 mg actually are
Real, FDA-approved strengths — and steps, not listed maintenance stops. The label lists 5, 10, and 15 mg as maintenance doses for weight. It does not list 7.5 or 12.5 mg.
That surprises people, so say it clearly: 7.5 mg and 12.5 mg exist. You can be prescribed them. If a chart you're looking at only shows 2.5, 5, 10, and 15 mg, it is incomplete under the current label.
Do you have to increase your Zepbound dose every four weeks?
No. Only the first increase is directed. The FDA label instructs patients to move from 2.5 mg to 5 mg after four weeks, but for every step after that it says the dosage may be increased in 2.5 mg increments after at least four weeks at the current dose. Later increases depend on how you're responding and how well you're tolerating the medicine. ([Prescribing Information][1])
This is the line that causes the confusion, and it's worth slowing down on.
Read the two instructions next to each other:
- First step: after four weeks at 2.5 mg, increase to 5 mg.
- Every step after: the dose may increase by 2.5 mg after at least four weeks at the current dose.
One is an instruction. The other is permission. "At least four weeks" sets a floor, not a deadline. There is no rule in the label that says you must go up every month.
So can you stay on 5 mg?
For weight, 5 mg is a listed maintenance dose. Whether it's the right long-term dose for you is a conversation with your prescriber — but you are not doing something wrong by being there.
Can you stay on 7.5 or 12.5 mg?
Those aren't listed as maintenance doses. If your prescription has been sitting at one of them for a while, that's worth a direct question at your next visit: "Is this my long-term dose, or are we still heading somewhere?" Don't guess, and don't change it yourself.
What actually drives the decision
The label says to consider treatment response and tolerability when choosing the maintenance dose. In plain terms: is it working, and can you live with the side effects? It also says that if you don't tolerate a maintenance dose, a lower maintenance dose can be considered. Going back down is a labeled option — not a failure.
If the wording felt contradictory, you didn't misread it. The label really does use a firm instruction for the first increase and permission-based language for every later increase.
Hold on to this section. It comes back later, and it's going to cost some of you money.
Which Zepbound doses are maintenance doses?
For weight reduction and long-term weight maintenance, the FDA-approved maintenance doses are 5 mg, 10 mg, or 15 mg once weekly. For moderate to severe obstructive sleep apnea in adults with obesity, they are 10 mg or 15 mg once weekly. In both cases the maximum dose is 15 mg once weekly, and 2.5 mg is a starting dose only. ([Prescribing Information][1])
| What you're being treated for | Starting dose | Maintenance doses | Maximum |
|---|---|---|---|
| Weight reduction and long-term maintenance | 2.5 mg | 5, 10, or 15 mg | 15 mg |
| Moderate to severe obstructive sleep apnea in adults with obesity | 2.5 mg | 10 or 15 mg only | 15 mg |
The sleep apnea difference
Look at that table again. If you're taking Zepbound for sleep apnea, 5 mg is not one of the listed maintenance options. The label lists only 10 and 15 mg.
That's a real difference. It matters because it changes where the labeled schedule is heading. Someone using Zepbound for weight may settle at 5 mg. For OSA, 5 mg is not the labeled maintenance endpoint. That also matters when planning refills, because a four-dose KwikPen can leave unused lower-strength doses if your prescription changes before the pen is finished.
Are Zepbound pen, vial, and KwikPen doses the same?
Yes — the same six strengths, 2.5 mg through 15 mg, are listed for every Zepbound presentation, and the dose schedule doesn't change based on which one you have. What changes is the amount of liquid per dose, how many doses are in the container, what supplies you need, how long it lasts, and the current access and payment path. ([Prescribing Information][1])
Here's the whole picture in one table. This is the part you probably came for.
| Feature | Single-dose pen | Single-dose vial | Multi-dose vial | KwikPen |
|---|---|---|---|---|
| Doses inside | 1 | 1 | 4 | 4 fixed doses |
| Liquid per dose | 0.5 mL | 0.5 mL | 0.6 mL | 0.6 mL |
| Needle and syringe | Needle built in | Separate syringe and needle | Separate syringe and needle | Separate compatible pen needle; not included |
| Priming needed? | No | No | No | Yes — before every weekly shot |
| Counting clicks to get a dose | N/A | N/A | N/A | The instructions say not to do it |
| Room-temperature limit | 21 total days at up to 86°F | 21 total days at up to 86°F | 30 total days at up to 86°F | 30 total days at up to 86°F |
| After first use | Discard after one injection | Discard after one injection | May be kept refrigerated or at room temperature; use the earliest discard limit | May be kept refrigerated or at room temperature; use the earliest discard limit |
| Throw it away when | Used, expired, frozen, damaged, or after 21 total room-temperature days | Used, expired, frozen, or after 21 total room-temperature days | Earliest of 30 total room-temperature days, 30 days after first use, or 4 weekly doses | Earliest of 30 total room-temperature days, 30 days after first use, or 4 weekly doses |
| Vision warning | Self-injection is not recommended if you are visually impaired; use caregiver or trained help | Self-injection is not recommended if you are visually impaired; use caregiver or trained help | Self-injection is not recommended if you are visually impaired; use caregiver or trained help | Self-injection is not recommended if you are visually impaired; use caregiver or trained help |
| Current consumer access, verified Aug. 6, 2026 | Insurance accepted through LillyDirect; commercial savings may apply | LillyDirect self-pay only; delivery or Walmart Pharmacy pickup | Listed in the current FDA-approved label, but active consumer dispensing was not confirmed | Select insurance and self-pay accepted through LillyDirect; delivery or Walmart Pharmacy pickup |
| Medicare GLP-1 Bridge | Not included | Not included | Not included | The only Zepbound form included, if the beneficiary meets CMS criteria and prior authorization is approved |
The device, vision, and storage rows come from the current prescribing information, [Medication Guide][14], and the matching [single-dose pen][3], [single-dose vial][4], and [KwikPen][2] instructions. The consumer access rows come from Lilly's current [LillyDirect Zepbound page][5]. The Medicare row comes from [CMS][9].
The right GLP-1 provider isn't the same for everyone — it depends on your state, your insurance and formulary, whether you want an FDA-approved or compounded medication, your preferred treatment path (injection or oral), and your budget. Because a general answer can't resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized provider match with source-verified pricing before you choose. → Find my GLP-1 treatment path — about 2 minutes. Matches on state, insurance, treatment path, device preference, and budget. It does not choose your medical dose.
Wait — four forms? Lilly's consumer page shows three.
It does, and here's why that gap exists.
Lilly announced that Zepbound KwikPen was available on February 23, 2026 and expanded self-pay access to major retail pharmacies on March 16, 2026. The current April 2026 prescribing information lists four presentations: the single-dose pen, the single-dose vial, a multi-dose vial, and the KwikPen. Lilly's current consumer page markets three: the single-dose pen, single-dose vial, and KwikPen. ([Lilly launch announcement][7]; [retail access announcement][8])
The multi-dose vial holds four 0.6 mL doses and uses the same preservative-containing formulation listed for the KwikPen, but it is drawn with a syringe instead of delivered through a pen.
Our honest position on the multi-dose vial: it is listed in the current FDA-approved label and has assigned product codes in the current prescribing information. But Lilly's consumer pages currently offer the single-dose vial and the KwikPen for self-pay, and we could not confirm that the multi-dose vial is being dispensed to patients through an active U.S. consumer channel. We're not going to tell you it's available when we can't prove it. If a pharmacy gives you one, stop and read the instructions that came with that exact vial. Ask the pharmacist to confirm the 0.6 mL presentation and show you how to measure it before you inject.
What's actually in the box
- Single-dose pens: cartons of 4. One dose per pen.
- Single-dose vials: cartons of 1 or 4. One dose per vial.
- Multi-dose vial: one vial containing 4 doses, as listed in the prescribing information. Current consumer availability is unconfirmed.
- KwikPen: carton of 1. Four fixed weekly doses. Pen needles are not included.
Why does one Zepbound device say 0.5 mL and another say 0.6 mL?
Milligrams are your prescribed dose. Milliliters are how much liquid carries that dose, and the volume is not the same across presentations. The single-dose pen and single-dose vial deliver each dose in 0.5 mL. The KwikPen and multi-dose vial deliver the same labeled milligrams in 0.6 mL. Never convert one presentation's volume into another presentation's instructions. ([Prescribing Information][1])
This is the fact with the highest chance of causing real harm, so we're going to be very concrete.
| Strength | Single-dose pen or vial | Multi-dose vial or KwikPen |
|---|---|---|
| 2.5 mg | 5 mg/mL in 0.5 mL | 4.17 mg/mL in 0.6 mL |
| 5 mg | 10 mg/mL in 0.5 mL | 8.33 mg/mL in 0.6 mL |
| 7.5 mg | 15 mg/mL in 0.5 mL | 12.5 mg/mL in 0.6 mL |
| 10 mg | 20 mg/mL in 0.5 mL | 16.7 mg/mL in 0.6 mL |
| 12.5 mg | 25 mg/mL in 0.5 mL | 20.8 mg/mL in 0.6 mL |
| 15 mg | 30 mg/mL in 0.5 mL | 25 mg/mL in 0.6 mL |
Look down that table. The multi-dose versions are about 17% less concentrated at every strength. Same milligrams. More liquid.
If you use vials, the printed mL is the number that matters
The official single-dose-vial instructions tell the user to use a syringe and needle recommended by the healthcare provider and draw the medicine to the 0.5 mL line. The current prescribing information says vial users need a 1 mL syringe that can measure the 0.5 mL or 0.6 mL dose for the presentation prescribed. ([Single-dose vial Instructions for Use][4]; [Prescribing Information][1])
This page will not turn those mL amounts into an insulin-syringe “unit” chart. The approved instructions use milliliters, and the right syringe, needle, and technique must match the exact vial you were given.
If your box or vial now shows a different volume than the one you were trained to use, stop before injecting. Read the Instructions for Use in that package and call the pharmacy. Drawing 0.5 mL from a presentation labeled for a 0.6 mL dose would not deliver the full labeled dose.
One more difference: what's in the liquid
The single-dose pen and vial contain tirzepatide, sodium chloride, sodium phosphate, and water for injection. Acid or base may also be used to adjust the pH.
The multi-dose vial and KwikPen also contain benzyl alcohol (5.4 mg), glycerin (4.8 mg), and phenol (1.08 mg) per 0.6 mL dose. Those are added ingredients in the multi-dose formulation. ([Prescribing Information][1])
This isn't a warning by itself. It is a real formulation difference. If you know you have had a serious reaction to any listed ingredient, tell your prescriber or pharmacist before using that presentation.
Can you count KwikPen clicks or split a Zepbound vial?
No. The FDA-approved KwikPen Instructions for Use tell you to turn the dose knob all the way until it stops and specifically tell users not to count clicks when selecting the dose. The same instructions say not to inject leftover medicine and not to transfer Zepbound from the pen into a syringe. Single-dose vials are discarded after one use even if liquid remains. ([KwikPen Instructions for Use][2]; [single-dose vial Instructions for Use][4])
We're not being cautious for the sake of it. The instruction is right there in the FDA-approved document that ships in the box.
The four rules, straight from the official instructions: 1. Do not count clicks to select the dose. Turn the knob all the way until it stops. 2. Do not inject the leftover medicine after four doses. 3. Do not transfer Zepbound from your pen into a syringe. 4. Do not save or split an opened single-dose vial. Discard it after use, even if medicine is left.
Why is there medicine left in the pen at all?
Because the KwikPen contains extra volume to allow for priming. You prime the pen before each of the four injections, and each prime releases a small amount of medicine. The manufacturer built that extra liquid in so the device can deliver its four fixed doses.
That extra volume is priming allowance, not an approved fifth dose. After four weekly doses, the pen prevents you from dialing another full dose.
Why click-counting is a bad idea even though it seems clever
The pen is engineered to deliver one fixed, complete dose when the knob is turned fully. A partial turn is not an approved way to measure a smaller Zepbound dose. There is no approved click-to-milligram conversion.
We're aware that click charts float around online for various pens. We won't publish one. If your prescriber wants you on a smaller amount, the safe path is a prescription for the strength they choose — all six labeled strengths exist.
Which Zepbound form is right for you?
There is no single best Zepbound device. The single-dose pen may be simplest and can be the least expensive path for an eligible commercially insured patient whose plan covers Zepbound. The single-dose vial and KwikPen are current self-pay options at the same published dose-tier prices. The KwikPen is the only Zepbound form included in the Medicare GLP-1 Bridge. In practice, coverage and access can narrow the choice before personal preference does. ([LillyDirect][5]; [CMS][9])
That last sentence is the reframe, and it's the thing we'd most like you to walk away with.
Lilly's current consumer page accepts insurance for the single-dose pen and select insurance for the KwikPen. It lists the single-dose vial as LillyDirect self-pay only. That is the current structure as of August 6, 2026 — not a promise that every plan or pharmacy will cover every device.
Find your row
| Your situation | Form that may fit | Current price or access fact | What to say to your prescriber or pharmacist |
|---|---|---|---|
| Commercial insurance that covers Zepbound | Single-dose pen | Eligible patients may pay as little as $25 per 1-, 2-, or 3-month fill; terms and savings caps apply | "Can my prescription be written for the single-dose pen, and do I qualify for Lilly's savings card?" |
| Commercial insurance that doesn't cover Zepbound | Compare the $499 pen offer with a cash vial or KwikPen | $499 per one-month pen fill versus $299–$449 per 28 days for the current self-pay vial or KwikPen offers | "My plan excludes Zepbound. Which cash presentation fits my prescription and injection comfort?" |
| No insurance | Single-dose vial or KwikPen | Current LillyDirect self-pay prices are $299–$449 per 28 days | "I'm paying cash. Can we choose between the single-dose vial and KwikPen?" |
| Medicare Part D, seeking weight management, and Bridge-eligible | KwikPen only | $50 per monthly supply only after CMS eligibility and prior authorization are confirmed | "Do I meet the Medicare GLP-1 Bridge criteria for weight management, and can you submit the prior authorization?" |
| You have vision problems that make the device hard to inspect or read | Use trained help and compare presentations with your care team | Both pen instructions require trained help when vision is a problem | "Which presentation can I use safely with trained help?" |
| You don't want to handle or attach a needle | Single-dose pen | Needle is built in | "I'd prefer the single-dose pen because I don't want to attach a needle." |
| You want one device to hold four weekly doses | KwikPen | One pen holds four fixed doses; a new compatible pen needle is needed each week | "Can you make sure I have the KwikPen and compatible needles?" |
Two honest limitations, and where to go if they apply to you
If your prescription may change before all four KwikPen doses are used, the KwikPen can leave medicine you cannot transfer, combine, or turn into a different strength. That loss is not automatic. If your prescriber keeps you at the same strength, you can use all four fixed doses within the label's time limits. But if the strength changes after one, two, or three doses from a new pen, ask what to do before opening another one. We do the exact potential-cost math below.
If you have significant vision problems, self-injection is not recommended. The Medication Guide applies that warning across Zepbound presentations. Both pen Instructions for Use also say not to use the pen without trained help when vision is a problem. Do not assume the single-dose autoinjector removes that need. ([Medication Guide][14]; [KwikPen Instructions for Use][2]; [single-dose pen Instructions for Use][3])
🔧 Not sure which device you actually have?
Tell us what's printed on your box — the device name, strength, volume, and how many devices are in the carton — and the checker will identify the presentation, show what supplies it needs, point you to the matching official instructions, and calculate the earliest throw-away date.
It reads your package. It does not recommend or change your dose.
Zepbound Device & Throw-Away Date Checker
Use this checker when the box in your hand does not match the device you expected. It identifies the presentation from the package name, strength, volume, number of devices, and needle type, then applies the storage rules for that presentation. It never calculates a partial dose, converts clicks, or tells you to use leftover medicine.
Free label-matching tool
Zepbound Device & Throw-Away Date Checker
Match the fields printed on your package to the labeled presentation and mark the relevant discard limits. This tool does not calculate a dose, convert units, recommend a restart, or tell you to change treatment.
Most likely presentation: KwikPen
- Printed strength
- 5 mg
- Labeled volume
- 0.6 mL per dose / 2.4 mL total
- Designed doses
- 4
- Supplies
- New compatible pen needle for every dose; sharps container
The device and volume fields do not match this labeled presentation. Do not inject based on this result—read the package Instructions for Use and call your pharmacist.
Use the earliest of 30 room-temperature days, 30 days after first use, or four doses. Enter a first-use date to see the 30-day first-use limit for a multi-dose presentation.
If the box, volume, device, or training does not match, stop and ask the pharmacist before injecting. This tool is a package check, not medical advice.
What the checker asks
- What exact device name is printed on the box?
- What strength is printed: 2.5, 5, 7.5, 10, 12.5, or 15 mg?
- Does the box say 0.5 mL, 0.6 mL per dose, or 2.4 mL total?
- How many pens or vials came in the carton?
- Is the needle built in, does the device need a syringe, or does it need a pen needle?
- When did it first leave the refrigerator?
- Has it stayed at room temperature since then? If not, how much total time has it spent at room temperature?
- If it is multi-dose, when was it first used?
- How many weekly doses have already been taken from it?
What the checker gives you
- The most likely presentation, strength, and labeled volume
- How many doses the device is designed to hold
- The supplies that presentation needs
- A link to the matching official Instructions for Use
- The earliest discard date based on room-temperature time, first use, and doses taken
- A conflict warning when the answers do not match a real labeled presentation
Quick manual device check
| What is in your hand | What it most likely is | What that means |
|---|---|---|
| A disposable pen with a built-in hidden needle; one pen per injection | Single-dose pen | One 0.5 mL dose, then discard the whole pen |
| A small vial labeled as one dose and 0.5 mL | Single-dose vial | Draw the full labeled 0.5 mL dose with the syringe and needle recommended by your healthcare provider, then discard the opened vial |
| One vial labeled 2.4 mL total and four 0.6 mL doses | Multi-dose vial | Four doses are listed in the current label; follow the exact package instructions and pharmacist training |
| One prefilled pen labeled KwikPen and 2.4 mL total; separate pen needle required | KwikPen | Four fixed 0.6 mL doses; prime and use a new compatible needle for every injection |
If your answers conflict — for example, the box says KwikPen but the volume says 0.5 mL — do not guess which field is wrong. Call the pharmacist before injecting.
How long does each Zepbound form last before you throw it away?
Zepbound is normally stored in the refrigerator at 36°F to 46°F and must never be frozen. A single-dose pen or single-dose vial can spend a total of 21 days at room temperature up to 86°F. An unopened multi-dose vial or KwikPen can spend up to 30 days at room temperature, and once opened it may be stored in the refrigerator or at room temperature until the earliest applicable throw-away limit. ([Prescribing Information][1])
| Presentation | Unopened, in the refrigerator | At room temperature | Once opened or used |
|---|---|---|---|
| Single-dose pen | Use through the printed expiration date if stored correctly | 21 total days maximum at up to 86°F | Single use — discard after the injection |
| Single-dose vial | Use through the printed expiration date if stored correctly | 21 total days maximum at up to 86°F | Discard after the injection, even if liquid remains |
| Multi-dose vial | Use through the printed expiration date if stored correctly | 30 total days maximum at up to 86°F | Refrigerator or room temperature; discard at the earliest of the three limits below |
| KwikPen | Use through the printed expiration date if stored correctly | 30 total days maximum at up to 86°F | Refrigerator or room temperature; discard at the earliest of the three limits below |
Never freeze it. Never use it if it has been frozen. Keep it in the original carton, away from light and heat. If you're not sure how long it has been out or how hot it got, call the pharmacy rather than guessing.
The word “total” matters
The label counts total time at room temperature. Cooling the device again does not erase time it already spent out of the refrigerator.
- For a single-dose pen or vial, keep a running total of room-temperature time and discard after 21 total days.
- An opened KwikPen or multi-dose vial may be stored in the refrigerator or at room temperature, but the first-use and four-dose clocks keep running either way.
The label does not say that returning a single-dose pen or vial to the refrigerator resets its 21-day clock. Do not restart the count.
The three separate throw-away deadlines for the KwikPen
This is the deadline to mark. Once you've used a KwikPen or multi-dose vial, throw it away when any one of these hits — whichever comes first:
- 30 total days at room temperature, or
- 30 days after first use, or
- after four weekly doses.
The date to write down is the day you take your first dose from that pen or vial, not the day you picked it up.
The Zepbound KwikPen's 30-day clock versus your four doses
A Zepbound KwikPen holds four weekly doses but must be thrown away no later than 30 days after the first one. On a regular weekly schedule, the fourth dose lands on day 21, which leaves nine days of slack. If later doses drift, that slack can run out, and the discard deadline still controls even when medicine remains. ([KwikPen Instructions for Use][2]; [Prescribing Information][1])
Here's the arithmetic. It takes 20 seconds to check.
| Event | Day |
|---|---|
| Dose 1 — starts the 30-day clock | Day 0 |
| Dose 2 | Day 7 |
| Dose 3 | Day 14 |
| Dose 4 | Day 21 |
| 30-day throw-away point | Day 30 |
| Slack between dose 4 and day 30 | 9 days |
Nine days. That's your whole margin.
Now put that next to two other rules from the same label. You may take a missed dose within four days. And you may change your injection day as long as two doses stay at least three days apart.
If each later dose drifts four days without moving back toward the earlier weekly day, dose four can land on day 33. That is three days after the pen's 30-day first-use limit.
Both rules are real. They solve different problems, and the earlier discard limit still controls. This is not a recommendation to stretch the schedule. It is a reason to write the first-use date on the pen and check the calendar before each injection.
If you use single-dose pens or vials, the same multi-dose first-use clock does not connect four separate devices. Each unopened device keeps its own printed expiration date and storage history.
🔧 Work out your own dates
Calculate my throw-away date →
Enter the date of your first injection from this pen. The checker shows your four weekly dates, the 30-day limit, and a clear warning if a planned injection falls outside the allowed window.
Dates only. Your prescriber decides when your dose changes.
What happens to unused KwikPen doses if your prescription changes?
One Zepbound KwikPen holds four fixed doses at one strength. If your prescriber changes the strength after you use only one, two, or three doses from a new pen, the remaining doses cannot be transferred, combined, or turned into a different dose. At a $449 four-dose offer price, each dose represents $112.25 of purchase value. The table below measures one specific way that value can be stranded: the prescribed strength changes before the pen is finished.
Remember the section about not having to move up every four weeks? Here's the possible bill.
The KwikPen is built around a four-dose rhythm. Four doses, one device. If you use all four doses at the same strength, nothing is left.
But if the prescribed strength changes after dose five, six, or seven at that strength, the second pen has already been opened. The table below shows what could remain inside it.
| If the prescription changes after this many weekly doses at one strength | KwikPens opened | Doses used | Doses potentially left in the open pen | Purchase value left at a $449 pen price |
|---|---|---|---|---|
| 4 weeks | 1 | 4 of 4 | 0 | $0 |
| 5 weeks | 2 | 5 of 8 | 3 | $336.75 |
| 6 weeks | 2 | 6 of 8 | 2 | $224.50 |
| 7 weeks | 2 | 7 of 8 | 1 | $112.25 |
| 8 weeks | 2 | 8 of 8 | 0 | $0 |
This is a potential unused-dose table, not a direction to throw medicine away. Your prescriber may keep you at the same strength long enough to use all four doses. If the prescription changes, ask what to do. Do not combine KwikPen doses, transfer medicine to a syringe, or create a new dose yourself.
Why single-dose forms behave differently
If you have unused single-dose pens or vials, each one stays sealed until you use it. An unopened device may remain stored within its printed expiration date and label storage limits.
That does not mean you should reach for an old strength on your own. It means an unused sealed dose is not automatically lost just because a new month started. Use it only if your current prescriber still directs that strength and the device has been stored correctly.
So here's the practical version: if your dose timing is uncertain and you're paying cash, single-dose vials can be easier to manage because Lilly currently lists the vial and KwikPen at the same dose-tier self-pay prices. The KwikPen wins on one-device convenience. The vial wins on keeping each unused dose sealed. Now you can choose with the tradeoff in plain sight.
How much does each Zepbound form cost in 2026?
Lilly currently advertises the same self-pay prices for a Zepbound single-dose vial and KwikPen: $299 per 28 days for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg. The first eligible 7.5–15 mg purchase gets the $449 offer automatically. To keep that price on later fills, the refill purchase must be completed within 45 days of the prior delivery or received date. Without the offer, the published regular price is $499 for 7.5 mg and $699 for 10, 12.5, and 15 mg. ([LillyDirect][5]; [Lilly savings terms][6])
All prices verified directly on Lilly's published pages and terms on August 6, 2026. Programs can change.
| Dose | Vial or KwikPen — qualifying self-pay price* | Vial or KwikPen — published regular price | Single-dose pen — eligible commercial plan covers it | Single-dose pen — commercial plan does not cover it |
|---|---|---|---|---|
| 2.5 mg | $299 | $299 | As low as $25 per eligible 1-, 2-, or 3-month fill | As low as $499 per one-month fill |
| 5 mg | $399 | $399 | As low as $25 per eligible 1-, 2-, or 3-month fill | As low as $499 per one-month fill |
| 7.5 mg | $449 | $499 | As low as $25 per eligible 1-, 2-, or 3-month fill | As low as $499 per one-month fill |
| 10 mg | $449 | $699 | As low as $25 per eligible 1-, 2-, or 3-month fill | As low as $499 per one-month fill |
| 12.5 mg | $449 | $699 | As low as $25 per eligible 1-, 2-, or 3-month fill | As low as $499 per one-month fill |
| 15 mg | $449 | $699 | As low as $25 per eligible 1-, 2-, or 3-month fill | As low as $499 per one-month fill |
* For the vial or KwikPen, a “month” is 28 days: either four single-dose vials or one four-dose KwikPen. The first eligible 7.5–15 mg purchase receives the $449 offer automatically. Later $449 fills require a completed refill purchase within 45 days of the prior delivery or received date under the applicable program terms.
Notice something in that table: the vial and the KwikPen currently cost the same at each self-pay dose tier. Four vials or one four-dose pen, same published starting price. So if you're paying cash, choosing between them is mainly a device, convenience, storage, and possible unused-dose decision.
There are three price paths for the single-dose pen, not two
A two-line price summary can hide the third path. Lilly's current terms are more specific:
- Commercial insurance that covers Zepbound → as low as $25 per eligible 1-, 2-, or 3-month prescription fill. Savings caps and other terms apply.
- Commercial insurance that does not cover Zepbound → as low as $499 per one-month prescription fill under the current card terms.
- No commercial insurance → the single-dose-pen savings card is not available. Compare the current LillyDirect self-pay vial and KwikPen offers instead.
If your plan excludes weight-loss medication, compare $499 for the single-dose pen against $299–$449 for a cash vial or KwikPen before you assume the pen is your only option.
The annual fill caps are not apples to apples
The current 2026 savings terms set different caps for different programs:
| Program | Maximum fills in 2026 | What one fill can cover |
|---|---|---|
| Covered-commercial single-dose pen card | Up to 13 fills | An eligible 1-, 2-, or 3-month prescription fill |
| Noncovered-commercial single-dose pen card | Up to 13 fills | One 28-day fill of up to four single-dose pens |
| KwikPen savings-card programs | Up to 11 fills | One 28-day KwikPen per fill |
That means “13 versus 11” cannot be turned into a simple days-of-coverage comparison. Covered pen-card fills may cover one, two, or three months; noncovered pen and KwikPen fills are one month. LillyDirect's direct self-pay purchase offer has separate terms.
The cited 2026 savings-card programs currently expire on December 31, 2026. Check the live terms before every refill instead of assuming this year's limits carry into 2027.
The most expensive detail on this page
The 45-day refill rule after the first eligible higher-dose purchase. Miss it at 10, 12.5, or 15 mg and the published price can move from $449 to $699. That's a $250 difference on one fill. At 7.5 mg, the published difference is $50.
Set a phone reminder for day 35 after the delivery or received date for each fill. That gives you room to handle a prescription or fulfillment delay before the 45-day deadline. Then verify the current offer before ordering.
If you don't know whether your plan covers Zepbound, find out before you pick a form
Everything above turns on one question you may not have answered yet: does your plan cover the Zepbound single-dose pen? Because that answer can decide whether an eligible fill is as low as $25 or whether a cash vial or KwikPen makes more sense.
Ro's free GLP-1 Insurance Coverage Checker currently checks coverage for the Zepbound single-dose pen. It does not currently check the Zepbound KwikPen. Ro says it contacts the insurer and sends a personalized coverage report. If you later join Ro Body, its insurance concierge says it can handle prior-authorization paperwork. Ro Body is separate from the free checker: it costs $39 for the first month, then $149 per month, or as low as $74 per month with an annual plan paid upfront. Medication costs are separate. ([Ro coverage checker][11]; [Ro insurance concierge][12]; [Ro Body pricing][16])
→ Check whether your plan covers the Zepbound pen with Ro (affiliate link)
If your plan covers the Zepbound single-dose pen, the eligible savings-card price may be your cheapest path — and you do not need Ro to use Lilly's card. Ask your prescriber for the pen and review the current official Lilly savings terms before the prescription is filled.
What else do you need to buy with each Zepbound form?
The Zepbound single-dose pen includes its needle, so it does not need a separate needle or syringe. Single-dose and multi-dose vials require a new syringe and needle for every injection. The KwikPen requires a new compatible pen needle for each of its four doses, and those needles are not included in the box. Every injectable form also needs safe sharps disposal. ([LillyDirect][5]; [KwikPen Instructions for Use][2]; [single-dose pen Instructions for Use][3]; [single-dose vial Instructions for Use][4])
| Form | What comes with it | What you still need |
|---|---|---|
| Single-dose pen | Needle built in | FDA-cleared sharps container or allowed heavy-duty household container; gauze or cotton if needed |
| Single-dose vial | Vial only | New syringe and needle for each dose, alcohol swab, gauze, sharps container |
| Multi-dose vial | Vial only | New syringe and needle for each dose, sharps container, and any other supplies named in the package instructions |
| KwikPen | Pen only | New compatible pen needle for every dose, alcohol swab, gauze or cotton, sharps container |
The KwikPen box does not contain needles
This can catch you at pickup. You get the pen home, open it, and there is nothing to attach.
Lilly's current page says pen needles must be purchased and can be added at checkout through LillyDirect. At another pharmacy, ask the pharmacist or prescriber to make sure compatible needles are ready before you leave. Do not assume the KwikPen box contains them.
Priming — the step only the KwikPen has
You prime the KwikPen before every weekly shot, not just the first one. Follow the current Instructions for Use: attach a new needle, turn to the prime position, hold the pen with the needle pointing up, tap it, and press until medicine appears at the tip. ([KwikPen Instructions for Use][2])
Priming checks medicine flow and prepares the pen for the full fixed dose. The pen contains extra volume for this step.
Two other habits matter: take the needle off after every shot and never share your KwikPen with anyone, even with a new needle. Sharing can spread a serious infection.
What should you do if you miss a Zepbound dose?
If you miss a Zepbound dose, take it as soon as possible within four days, or 96 hours, of the missed dose. If more than four days have passed, skip that dose and take the next one on your regular day. You may change which day of the week you inject as long as there are at least three days, or 72 hours, between two doses. ([Prescribing Information][1])
| How late are you? | What the label says to do |
|---|---|
| 4 days or less | Take it as soon as you can, then return to your regular weekly schedule |
| More than 4 days | Skip it. Take the next dose on your normal day |
| Want to switch days permanently | Fine — just keep at least 3 days, or 72 hours, between doses |
| Missed several weeks | Call your prescriber before restarting |
Never double up. Do not take two doses less than 72 hours apart.
If you missed more than one week, call before you restart
We looked for a restart rule and there isn't one. The Zepbound label does not publish a universal instruction for restarting after a long gap. That's a real gap, not an oversight on our part.
Tirzepatide has a half-life of about five to six days, which means a long interruption changes how much medicine remains in the body. The right restart plan can depend on the old dose, the length of the gap, side effects, and your health history. ([Prescribing Information][1])
Do not build your own restart schedule from a dose chart — including this one. Call your prescriber.
What should you check before moving up a Zepbound dose?
Before increasing a Zepbound dose, the label tells prescribers to consider treatment response and tolerability and to allow at least four weeks at the current dose. It also tells anyone using oral hormonal birth control to add a barrier method or switch to a non-oral method for four weeks after every dose increase — not only when starting the medication. ([Prescribing Information][1])
That second point deserves its own headline because it changes what someone should do after every increase.
🔴 If you take birth control pills, read this before every dose increase
Zepbound slows how fast the stomach empties, which can affect how well some swallowed medicines are absorbed. The label's instruction is specific and repeating:
Switch to a non-oral birth control method, or add a barrier method, for four weeks after you start Zepbound — and for four weeks after each dose increase.
Not once at the beginning. Every time you go up. If someone makes all five possible increases between 2.5 mg and 15 mg, that creates five separate four-week backup windows after those increases.
Non-oral hormonal birth control should not be affected by this delayed-stomach-emptying effect.
If you are pregnant or become pregnant
The label says Zepbound may cause fetal harm and should be stopped when pregnancy is recognized. Weight loss is not recommended during pregnancy. Contact your prescriber promptly if you become pregnant or plan to become pregnant. ([Prescribing Information][1]; [Medication Guide][14])
Do not stack Zepbound with another tirzepatide or GLP-1 medicine
Zepbound contains tirzepatide. The label says using it with another tirzepatide-containing product or with another GLP-1 receptor agonist is not recommended. That includes trying to “bridge” a dose by adding another GLP-1 product on your own.
If you use insulin or a sulfonylurea
Zepbound can lower blood sugar. The risk of low blood sugar is higher when it is used with insulin or a sulfonylurea. Ask the prescriber whether those doses need to change and how to watch for low blood sugar before starting Zepbound or moving up. ([Prescribing Information][1]; [Medication Guide][14])
If you have severe gastroparesis
The label does not recommend Zepbound for people with severe gastroparesis, a condition in which the stomach empties very slowly. Tell the prescriber before starting or increasing Zepbound if you have been diagnosed with it. ([Prescribing Information][1])
Symptoms that shouldn't wait for your next appointment
The label's warning and patient-counseling sections separate routine side effects from symptoms that need prompt action.
Stop Zepbound and seek prompt medical help for signs of a serious allergic reaction, such as swelling of the face, lips, tongue, or throat; trouble breathing or swallowing; fainting; or a severe rash.
Stop Zepbound and contact your healthcare provider promptly for severe or persistent abdominal pain, especially if it spreads to the back, with or without nausea or vomiting. That can be a sign of pancreatitis.
Contact your healthcare provider for:
- Severe or ongoing stomach problems that will not settle
- Vomiting or diarrhea that keeps going, especially with dehydration
- Pain in your upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools — possible signs of gallbladder trouble
- A lump or swelling in your neck, a hoarse voice that will not go away, or trouble swallowing or breathing
- Vision changes if you have type 2 diabetes
Tell every member of your care team you're on Zepbound before any surgery or procedure using general anesthesia or deep sedation. The medicine can slow stomach emptying, which can raise the risk of stomach contents entering the lungs during a procedure. ([Prescribing Information][1]; [Medication Guide][14])
Who shouldn't take Zepbound at all
The label lists these as contraindications:
- A personal or family history of medullary thyroid carcinoma, or MTC
- Multiple Endocrine Neoplasia syndrome type 2, or MEN 2
- A known serious allergic reaction to tirzepatide or any ingredient in Zepbound
Zepbound also carries a boxed warning about thyroid C-cell tumors seen in rats. Whether that risk applies to humans has not been determined. Read the full Medication Guide that came with your prescription.
What we actually verified — and what we couldn't
Every dose, volume, storage rule, and warning on this page comes from the current FDA-approved Zepbound prescribing information, Medication Guide, or presentation-specific Instructions for Use. Every price comes from Eli Lilly's own published pages or terms read on August 6, 2026. Medicare facts come from CMS. Where we could not confirm something, we say so instead of filling the gap with a guess.
✅ What we opened and read ourselves
| What we checked | Primary source | Verified |
|---|---|---|
| Dose schedule, all four presentations listed in the current FDA-approved label, volumes, ingredients, storage, warnings | Zepbound Prescribing Information, revised April 2026 | Aug. 6, 2026 |
| Priming, four fixed doses, “do not count clicks,” leftover-medicine rule, needle requirements | Zepbound KwikPen Instructions for Use | Aug. 6, 2026 |
| Single-dose pen operation, built-in needle, vision warning | Zepbound Single-Dose Pen Instructions for Use | Aug. 6, 2026 |
| Single-dose vial supplies, 0.5 mL instruction, single-use disposal | Zepbound Single-Dose Vial Instructions for Use | Aug. 6, 2026 |
| Patient instructions, vision warning, overdose, pregnancy, and serious-symptom guidance | Zepbound Medication Guide, revised April 2026 | Aug. 6, 2026 |
| Current vial, KwikPen, and pen access and prices | LillyDirect Zepbound page and current Lilly savings terms | Aug. 6, 2026 |
| KwikPen launch and retail self-pay expansion dates | Lilly announcements dated Feb. 23 and Mar. 16, 2026 | Aug. 6, 2026 |
| Medicare GLP-1 Bridge formulation, $50 copay, dates, and eligibility limits | CMS Medicare GLP-1 Bridge pages | Aug. 6, 2026 |
| What Ro's free checker covers and what its concierge does | Ro's current coverage-checker and insurance pages | Aug. 6, 2026 |
🔧 Original work on this page
These are calculations or assembled comparisons we produced from the primary sources above:
- The “earliest week possible” column — stacking the label's minimum four-week gaps to get week 21 for 15 mg.
- The nine-day KwikPen slack figure — the gap between dose four on day 21 and the day-30 first-use limit.
- The potential unused-dose value table — what can remain in a four-dose pen when a prescription changes after five, six, or seven weekly doses at one strength.
- The four-presentation decision matrix — one table joining dose volume, supplies, storage, consumer access, and Medicare treatment for every presentation listed in the current FDA-approved label.
⚠️ What we could not confirm
- Whether the multi-dose vial is being dispensed through an active U.S. consumer channel. It is in the FDA-approved label with assigned product codes, but Lilly's consumer page currently markets three formats.
- Whether any given pharmacy stocks every marketed form. Availability varies. Call first.
- What your insurance will pay. A web page cannot guarantee a plan decision. Confirm directly with the plan.
- A universal restart dose after a long break. The label does not publish one, so neither do we.
- Whether a specific leftover device remains appropriate for you after a prescription change. That is a prescriber and pharmacist decision.
Who wrote this and why
Who: The RX Index. How: By reading the current prescribing information, presentation-specific Instructions for Use, Lilly's dated pricing terms, CMS rules, and current access pages side by side, then reconciling them into one dataset and showing the arithmetic the sources leave out. Why: Because the current label has six strengths and four presentations, while Lilly's current consumer page markets three formats. That creates avoidable confusion around 0.5 versus 0.6 mL, one versus four doses, and three different discard clocks.
This page has not been reviewed by a clinician. We're telling you that instead of claiming otherwise. Every dose, device, and safety rule here is traced to the FDA-approved prescribing information, Medication Guide, or Instructions for Use.
Why there are no testimonials on this page
We don't publish customer testimonials on dosing pages. A review can't establish a dose, a storage rule, or a safe injection — and putting weight-loss success stories next to injection instructions would be both promotional and unhelpful.
The proof here is the source record, the visible verification date, and the calculations you can check yourself.
Zepbound dose chart FAQ
Is the Zepbound dose chart the same for the pen, vial, and KwikPen? Yes. All four presentations listed in the current FDA-approved label come in the same six strengths, and the labeled escalation schedule is the same. What differs is the liquid volume per dose, how many doses each container holds, the supplies it needs, and its storage limits.
How many doses are in a Zepbound KwikPen? Four fixed doses. One is taken each week. The pen must be discarded after the fourth dose even if medicine remains.
How much liquid do I draw from a Zepbound vial? The official single-dose vial instructions use 0.5 mL. The current prescribing information lists 0.6 mL per dose for the multi-dose vial. Use the syringe recommended by your healthcare provider and follow the instructions that came with the exact vial. Do not use an online “unit” conversion chart.
Is 2.5 mg a maintenance dose? No. The label says 2.5 mg is for treatment initiation and is not approved as a maintenance dose. It is the first four-week step in the labeled schedule.
Is 7.5 mg or 12.5 mg a maintenance dose? Both are FDA-approved strengths and valid steps during dose escalation, but neither is listed as a maintenance dose. The listed maintenance doses for weight are 5, 10, and 15 mg.
Do I have to increase my Zepbound dose every four weeks? No. The first move from 2.5 mg to 5 mg after four weeks is directed. Later increases may happen only after at least four weeks, based on response and tolerability.
How long does it take to reach 15 mg? Week 21 is the earliest point allowed by the label if every later increase happens after exactly four weeks. That is a calculation, not a personal schedule, and 5 mg or 10 mg may be a labeled maintenance dose for weight treatment.
Is Zepbound dosing different for sleep apnea? The starting dose and escalation steps are the same, but the listed maintenance doses for obstructive sleep apnea are 10 mg and 15 mg. The 5 mg maintenance option applies to weight treatment, not OSA.
Is the KwikPen an autoinjector? No. Unlike the single-dose pen, the KwikPen needs a compatible pen needle attached, priming before every dose, and the dose knob turned fully until it stops.
Do I need to prime the KwikPen every week? Yes. The official instructions say to prime before each weekly injection, not only before the first one.
Can I count clicks on the KwikPen to get a smaller dose? No. The FDA-approved instructions tell you not to count clicks and to turn the dose knob all the way until it stops. There is no approved click-to-milligram conversion.
Can I use the medicine left in a KwikPen after four doses? No. Discard the pen after four doses. The instructions say not to inject the leftover medicine and not to transfer it into a syringe.
Can I save part of a single-dose vial? No. Single-dose vials are discarded after one injection, even if liquid remains.
Can I put Zepbound back in the refrigerator? An opened KwikPen or multi-dose vial may be stored in the refrigerator or at room temperature. For a single-dose pen or vial, the label sets a total 21-day room-temperature limit and does not say that cooling it again resets that count. Keep a running total and ask the pharmacist if the storage history is unclear.
When exactly do I throw away a KwikPen? At the earliest of these three points: 30 total days at room temperature, 30 days after first use, or four weekly doses. Mark the first-use date on the pen.
Do I need a prescription for KwikPen needles? The box does not include needles, and compatible pen needles must be obtained separately. LillyDirect says they can be purchased at checkout. At another pharmacy, ask the pharmacist or prescriber how they should be supplied before you leave with the pen.
Which Zepbound form is cheapest? It depends on insurance and program eligibility. With covered commercial insurance, the single-dose pen may be as low as $25 per eligible 1-, 2-, or 3-month fill. For current cash-pay offers, the single-dose vial and KwikPen are both $299–$449 per 28 days, depending on dose and offer terms.
Does Medicare cover the Zepbound KwikPen? The Medicare GLP-1 Bridge includes only the Zepbound KwikPen, not the single-dose pen or vial. Eligible Part D beneficiaries pay a $50 monthly copay after the prescriber submits a prior authorization and CMS criteria are met. The Bridge is only for qualifying weight-management use and runs from July 1, 2026, through December 31, 2027. A beneficiary with type 2 diabetes, moderate to severe obstructive sleep apnea, or noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-advanced liver scarring is ineligible for the Bridge even if the weight-management criteria would otherwise be met; the coverage request goes to the Part D plan. Pen needles are not covered by the Bridge and must be bought separately. ([CMS provider information][10]; [CMS pharmacy information][9]) See our full Medicare GLP-1 Bridge guide →
What if the pharmacy gives me a different device than last time? Stop before injecting. The label says patients need presentation-specific training whenever the prescribed presentation changes. Read the new Instructions for Use and ask the pharmacist to walk you through it.
What if I missed several weeks of Zepbound? Call your prescriber. The label does not publish a universal restart dose after a long interruption, and tirzepatide's half-life of about five to six days means a long gap changes how much medicine remains in the body. ([Prescribing Information][1])
What if I took too much Zepbound or took two doses too close together? Call your healthcare provider or Poison Help at 1-800-222-1222, or go to the nearest emergency room right away. Do not wait for symptoms or try to correct it with another dose. ([Medication Guide][14])
Can I take Zepbound with Mounjaro or another GLP-1 medicine? The label says using Zepbound with another tirzepatide-containing product or another GLP-1 receptor agonist is not recommended. Do not combine them on your own.
What if I become pregnant while taking Zepbound? Contact your prescriber promptly. The label says Zepbound may cause fetal harm and should be stopped when pregnancy is recognized.
What if I take insulin or a sulfonylurea? The risk of low blood sugar is higher when Zepbound is used with insulin or a sulfonylurea. Ask the prescriber whether either dose needs to change and how to watch for low blood sugar. Do not change those medicines on your own. ([Prescribing Information][1]; [Medication Guide][14])
Can I use Zepbound if I have severe gastroparesis? The label does not recommend Zepbound for people with severe gastroparesis. Tell the prescriber before starting or increasing Zepbound if you have been diagnosed with it. ([Prescribing Information][1])
Is compounded tirzepatide a generic Zepbound? No. Compounded tirzepatide is not an FDA-approved generic Zepbound. FDA says compounded drugs and generic drugs are not the same: generic drugs are FDA-approved, while compounded drugs are not. Compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before marketing. ([FDA compounded GLP-1 concerns][13]; [FDA compounding Q&A][15])
Is Zepbound approved for children? No. The current U.S. label is for adults, and Zepbound's safety and effectiveness have not been established in children.
Where can I inject Zepbound? The abdomen or thigh, or the back of the upper arm if another person gives the injection. Rotate the site each week. Zepbound can be taken at any time of day, with or without food.
Still deciding how to get Zepbound?
If you already have a prescription and a device, you're done — go check your box against the tables above and mark your throw-away date.
If you're still working out how to actually get this, that's a different question with a lot of moving parts: your state, your insurance, whether the single-dose pen, vial, or KwikPen makes more sense for you, and what you're willing to spend.
Still not sure which GLP-1 program is right for you? Take our free 2-minute matching quiz.
Matches on state, insurance, treatment path, device preference, and budget, with source-verified pricing. It will not choose your medical dose.
Related guides
- How to get the Zepbound KwikPen online — if you've decided on the KwikPen and just need to get one
- Zepbound KwikPen through the $50 Medicare GLP-1 Bridge
- How to switch from Mounjaro to Zepbound
- How to switch from compounded tirzepatide to Zepbound
Sources
- [Zepbound (tirzepatide) Prescribing Information, Eli Lilly and Company, revised April 2026][1]
- [Zepbound KwikPen Instructions for Use, Eli Lilly, revised January 2026][2]
- [Zepbound Single-Dose Pen Instructions for Use, Eli Lilly, revised April 2026][3]
- [Zepbound Single-Dose Vial Instructions for Use, Eli Lilly, revised April 2026][4]
- [LillyDirect Zepbound device, access, and self-pay page][5]
- [Zepbound Full Terms and Conditions, Eli Lilly][6]
- [Lilly announcement: Zepbound KwikPen available, February 23, 2026][7]
- [Lilly announcement: KwikPen self-pay access expanded to major pharmacies, March 16, 2026][8]
- [CMS Medicare GLP-1 Bridge information for pharmacies][9]
- [CMS Medicare GLP-1 Bridge information for providers][10]
- [Ro GLP-1 Insurance Coverage Checker][11]
- [Ro Body insurance and prior-authorization support][12]
- [FDA: Concerns with unapproved GLP-1 drugs used for weight loss][13]
- [Zepbound Medication Guide, Eli Lilly, revised April 2026][14]
- [FDA: Compounding and the FDA — Questions and Answers][15]
- [Ro Body membership pricing][16]
Medical disclaimer
This page is health information, not medical advice. It summarizes the FDA-approved Zepbound label and publicly posted manufacturer, CMS, and provider information as of August 6, 2026. It does not replace the prescription, Medication Guide, or Instructions for Use that came with your specific device, and it cannot account for your personal medical situation. Always follow your prescriber's instructions and the documents that shipped with your medication. If your device, dose, volume, or packaging doesn't match what you expected, contact your pharmacist or prescriber before injecting.
[1]: https://pi.lilly.com/us/zepbound-uspi.pdf [2]: https://pi.lilly.com/us/zepbound-kwikpen-us-ifu.pdf [3]: https://pi.lilly.com/us/zepbound-pen-us-ifu.pdf [4]: https://pi.lilly.com/us/zepbound-vial-us-ifu.pdf [5]: https://www.lilly.com/lillydirect/zepbound [6]: https://www.lilly.com/lillydirect/zepbound/zepbound-tirzepatide-full-terms-conditions [7]: https://investor.lilly.com/news-releases/news-release-details/zepbound-tirzepatide-most-prescribed-weight-management [8]: https://investor.lilly.com/news-releases/news-release-details/media-statement-zepbound-tirzepatide-kwikpen-now-available-self [9]: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-pharmacies [10]: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers [11]: https://ro.co/weight-loss/glp1-insurance-checker/ [12]: https://ro.co/weight-loss/insurance/ [13]: https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss [14]: https://pi.lilly.com/us/zepbound-us-mg.pdf [15]: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers [16]: https://ro.co/weight-loss/pricing/